TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy.
TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy.
复制标题
糖尿病视网膜病变患者血清TGF-β水平及抗vegf治疗的作用
DOI：
10.3390/ijms21249558
复制
发表时间：
2020-12-15
影响因子：
5.6
通讯作者：
Bucolo C
中科院分区：
文献类型：
--
作者：
Bonfiglio V;Platania CBM;Lazzara F;Conti F;Pizzo C;Reibaldi M;Russo A;Fallico M;Ortisi E;Pignatelli F;Longo A;Avitabile T;Drago F;Bucolo C
转化生长因子 β1 (TGFβ1) 是一种促炎细胞因子，与糖尿病视网膜病变 (DR) 的发病机制有关，尤其是在疾病晚期。本研究的目的是验证血清 TGFβ1 作为 DR 阶段的诊断和预后生物标志物。 38 名受试者入组，在诊断和评估纳入和排除标准后，被分配到六组：(1) 健康年龄匹配对照，(2) 无 DR 的糖尿病患者，(3) 未接受过治疗的非增殖性糖尿病视网膜病变 (NPDR)，(4) 接受过玻璃体内 (IVT) 阿柏西普治疗的 NPDR，(5) 未接受过治疗的增殖性糖尿病视网膜病变 (PDR) 和 (6) 未接受过治疗的增殖性糖尿病视网膜病变 (PDR) IVT 阿柏西普。采用酶联免疫吸附试验（ELISA）测定血清血管内皮生长因子A（VEGF-A）、胎盘生长因子（PlGF）和TGFβ1水平。通过结构光学相干断层扫描（S-OCT）评估入组受试者的黄斑中心凹黄斑厚度（FMT）。与初治 DR 患者相比，接受阿柏西普治疗的 NPDR 和 PDR 患者的 VEGF-A 血清水平降低。 PlGF 血清水平仅在阿柏西普治疗的 NPDR 患者中受到调节。特别是，TGFβ1 血清水平可预测从 NPDR 到 PDR 的疾病进展。还进行了多变量方差分析 (M-ANOVA)，以评估固定因素对糖化血红蛋白 (HbA1c) 水平、TGFβ1 和糖尿病病程的影响。总之，我们的数据强化了 TGFβ1 将成为糖尿病视网膜病变的生物标志物和药理学靶点的假设。
Transforming growth factor β1 (TGFβ1) is a proinflammatory cytokine that has been implicated in the pathogenesis of diabetic retinopathy (DR), particularly in the late phase of disease. The aim of the present study was to validate serum TGFβ1 as a diagnostic and prognostic biomarker of DR stages. Thirty-eight subjects were enrolled and, after diagnosis and evaluation of inclusion and exclusion criteria, were assigned to six groups: (1) healthy age-matched control, (2) diabetic without DR, (3) non-proliferative diabetic retinopathy (NPDR) naïve to treatment, (4) NPDR treated with intravitreal (IVT) aflibercept, (5) proliferative diabetic retinopathy (PDR) naïve to treatment and (6) PDR treated with IVT aflibercept. Serum levels of vascular endothelial growth factor A (VEGF-A), placental growth factor (PlGF) and TGFβ1 were measured by means of enzyme-linked immunosorbent assay (ELISA). Foveal macular thickness (FMT) in enrolled subjects was evaluated by means of structural-optical coherence tomography (S-OCT). VEGF-A serum levels decreased in NPDR and PDR patients treated with aflibercept, compared to naïve DR patients. PlGF serum levels were modulated only in aflibercept-treated NPDR patients. Particularly, TGFβ1 serum levels were predictive of disease progression from NPDR to PDR. A Multivariate ANOVA analysis (M-ANOVA) was also carried out to assess the effects of fixed factors on glycated hemoglobin (HbA1c) levels, TGFβ1, and diabetes duration. In conclusion, our data have strengthened the hypothesis that TGFβ1 would be a biomarker and pharmacological target of diabetic retinopathy.
登录
查看更多内容
影响因子：
6
作者：
Dagher, Zeina;Gerhardinger, Chiara;Lorenzi, Mara
通讯作者：
Lorenzi, Mara
影响因子：
5
作者：
Fisichella, Vincenzo;Giurdanella, Giovanni;Bucolo, Claudio
通讯作者：
Bucolo, Claudio
影响因子：
3
作者：
Lane, PH;Snelling, DM;Langer, WJ
通讯作者：
Langer, WJ
DOI：
10.1900/rds.2015.12.159
发表时间：
2015-03-01
期刊：
The review of diabetic studies : RDS
影响因子：
--
作者：
Jenkins, Alicia J;Joglekar, Mugdha V;Januszewski, Andrzej S
通讯作者：
Januszewski, Andrzej S
影响因子：
3.7
作者：
Ang, Wen Jeat;Zunaina, Embong;Mahaneem, Mohamed
通讯作者：
Mahaneem, Mohamed